Cambridge, Mass. — Enveric Biosciences said it will participate in the 2026 BIO International Convention, which will be held June 22-25 in San Diego.
Enveric is a biotechnology company developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders.
“We are arriving at BIO with strong operational momentum, driven by the recently announced positive preclinical phototoxicity results and the initiation of IND-enabling GLP genotoxicity studies for EB-003,” said Joseph Tucker, Ph.D., CEO of Enveric Biosciences. “This milestone moves us steadily toward IND submission and Phase 1 clinical entry. We are looking forward to meeting with potential strategic partners at the convention to discuss our continued progress and the unique mechanism of EB-003.”
Members of Enveric’s management team will hold meetings throughout the convention. Registered attendees can request a meeting through the BIO One-on-One Partnering platform.
Enveric is focused on developing next-generation small-molecule therapeutics designed to promote neuroplasticity without hallucinogenic effects. The company’s lead candidate, EB-003, is designed to selectively engage both 5-HT2A and 5-HT1B receptors to deliver fast-acting and durable antidepressant and anxiolytic effects with outpatient convenience.
